Gogliettino, Marta (2014) Proteasome and Acylpeptide hydrolase system: exploring an alternative strategy in cancer therapy. [Tesi di dottorato]

[img]
Preview
Text
Tesi dottorato Marta Gogliettino.pdf

Download (11MB) | Preview
[error in script] [error in script]
Item Type: Tesi di dottorato
Lingua: English
Title: Proteasome and Acylpeptide hydrolase system: exploring an alternative strategy in cancer therapy
Creators:
CreatorsEmail
Gogliettino, Martamarta.gogliettino@libero.it
Date: 29 March 2014
Number of Pages: 159
Institution: Università degli Studi di Napoli Federico II
Department: Biologia
Scuola di dottorato: Scienze biologiche
Dottorato: Biologia applicata
Ciclo di dottorato: 26
Coordinatore del Corso di dottorato:
nomeemail
Ricca, Ezioericca@unina.it
Tutor:
nomeemail
Palmieri, GiannaUNSPECIFIED
Date: 29 March 2014
Number of Pages: 159
Uncontrolled Keywords: APEH,proteasome, cancer cells, protease inhibitors
Settori scientifico-disciplinari del MIUR: Area 05 - Scienze biologiche > BIO/10 - Biochimica
Date Deposited: 07 Apr 2014 15:38
Last Modified: 27 Jan 2015 13:59
URI: http://www.fedoa.unina.it/id/eprint/9769

Abstract

Acylpeptide hydrolase (APEH), one of the four members of the prolyl oligopeptidase class, catalyses the removal of Nacylated amino acids from acetylated peptides and it has been postulated to play a key role in protein degradation machinery. Disruption of protein turnover has been established as an effective strategy to down-regulate the ubiquitinproteasome system (UPS) and as a promising approach in anticancer therapy. Here, we illustrate a new pathway modulating UPS and proteasome activity through inhibition of APEH. To find novel molecules able to down-regulate APEH activity, we screened a set of synthetic peptides, reproducing the reactive-site loop of a known archaeal inhibitor of APEH (SsCEI), and the conjugated linoleic acid (CLA) isomers. A 12-mer SsCEI peptide and the trans10-cis12 isomer of CLA, were identified as specific APEH inhibitors and their effects on cell-based assays were paralleled by a dose-dependent reduction of proteasome activity. Moreover, cell treatment with the individual compounds increased the cytoplasm levels of several classic hallmarks of proteasome inhibition, such as NFkappaB and misfolded or polyubiquitinylated proteins, without any cytotoxicity. Remarkably, transfection of human bronchial epithelial cells with APEH siRNA, promoted a marked accumulation of a mutant of the cystic fibrosis transmembrane conductance regulator (CFTR), herein used as a model of misfolded protein typically degraded by UPS. Our study supports a previously unrecognized role of APEH as a negative effector of proteasome activity by an unknown mechanism and opens new perspectives for the development of strategies aimed at modulation of cancer progression.

Actions (login required)

View Item View Item